{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:12:11Z","timestamp":1786990331912,"version":"build-2736575974"},"reference-count":103,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI185663"],"award-info":[{"award-number":["R21AI185663"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.idc.2025.11.010","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T20:25:27Z","timestamp":1767039927000},"page":"79-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic Strategies for Extended-Spectrum \u03b2-Lactamase-Producing Organisms"],"prefix":"10.1016","volume":"40","author":[{"given":"Laura E.","family":"Wilkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.idc.2025.11.010_bib1","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s150100050041","article-title":"Occurrence of extended-spectrum \u03b2-lactamases (ESBL) in Dutch hospitals","volume":"27","author":"Stobberingh","year":"1999","journal-title":"Infection"},{"issue":"2","key":"10.1016\/j.idc.2025.11.010_bib2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1128\/AAC.28.2.302","article-title":"Evolution of plasmid-coded resistance to broad-spectrum Cephalosporins","volume":"28","author":"Kliebe","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2025.11.010_bib3","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/AAC.39.4.899","article-title":"SHV-7, a novel cefotaxime-hydrolyzing \u03b2-lactamase, identified in Escherichia coli isolates from hospitalized nursing home patients","volume":"39","author":"Bradford","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.010_bib4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0399-077X(05)81259-4","article-title":"Sensibilit\u00e9 aux b\u00e9talactamines de souches d\u2019E. coli isol\u00e9es en 1989 et 1993 dans 9 h\u00f4pitaux g\u00e9n\u00e9raux","volume":"24","author":"Allouch","year":"1994","journal-title":"M\u00e9decine Mal Infect"},{"key":"10.1016\/j.idc.2025.11.010_bib5","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.micpath.2017.11.061","article-title":"The prevalence and drug resistance pattern of extended spectrum \u03b2\u2013lactamases (ESBLs) producing Enterobacteriaceae in Africa","volume":"114","author":"Saravanan","year":"2018","journal-title":"Microb Pathog"},{"issue":"S1","key":"10.1016\/j.idc.2025.11.010_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/1120009X.2017.1380395","article-title":"Multi-drug-resistant gram-negative bacteria causing urinary tract infections: a review","volume":"29","author":"Mazzariol","year":"2017","journal-title":"J Chemother"},{"key":"10.1016\/j.idc.2025.11.010_bib7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/jtm\/taw102","article-title":"The ecology of extended-spectrum \u03b2-lactamases (ESBLs) in the developed world","volume":"24","author":"Doi","year":"2017","journal-title":"J Travel Med"},{"key":"10.1016\/j.idc.2025.11.010_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2024.107275","article-title":"Emerging threats: antimicrobial resistance in extended-spectrum \u03b2-lactamase and carbapenem-resistant Escherichia coli","volume":"200","author":"Aljohni","year":"2025","journal-title":"Microb Pathog"},{"issue":"8","key":"10.1016\/j.idc.2025.11.010_bib9","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.arcmed.2021.09.002","article-title":"Management of infections caused by multidrug-resistant gram-negative pathogens: recent advances and future directions","volume":"52","author":"Bassetti","year":"2021","journal-title":"Arch Med Res"},{"issue":"2","key":"10.1016\/j.idc.2025.11.010_bib10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/00313029600169813","article-title":"An evaluation of the in vitro activity of piperacillin\/tazobactam","volume":"28","author":"Daley","year":"1996","journal-title":"Pathology"},{"issue":"9","key":"10.1016\/j.idc.2025.11.010_bib11","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/cid\/civ003","article-title":"Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum \u03b2-lactamase bacteremia","volume":"60","author":"Tamma","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.idc.2025.11.010_bib12","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.idc.2025.11.010_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jgar.2024.08.002","article-title":"Piperacillin-tazobactam vs. carbapenems for treating hospitalized patients with ESBL-producing Enterobacterales bloodstream infections: a systematic review and meta-analysis","volume":"39","author":"Gatti","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"issue":"7","key":"10.1016\/j.idc.2025.11.010_bib14","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1128\/AAC.00365-16","article-title":"A multinational, preregistered cohort study of \u03b2-lactam\/\u03b2-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae","volume":"60","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2025.11.010_bib15","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1177\/1060028017748943","article-title":"Is it time to rethink the notion of Carbapenem-sparing therapy against extended-spectrum \u03b2-lactamase\u2013producing Enterobacteriaceae bloodstream infections? A critical review","volume":"52","author":"Chastain","year":"2018","journal-title":"Ann Pharmacother"},{"issue":"61","key":"10.1016\/j.idc.2025.11.010_bib16","first-page":"1","article-title":"Carbapenem-sparing strategies for ESBL producers: when and how","volume":"9","author":"Karaiskos","year":"2020","journal-title":"Antibiotics"},{"issue":"1","key":"10.1016\/j.idc.2025.11.010_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/Spectrum.00226-21","article-title":"In Vitro activity of Cefotetan against ESBL-producing Escherichia coli and Klebsiella pneumoniae bloodstream isolates from the MERINO trial","volume":"9","author":"Stewart","year":"2021","journal-title":"Microbiol Spectr"},{"issue":"1","key":"10.1016\/j.idc.2025.11.010_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106361","article-title":"Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study","volume":"58","author":"Delory","year":"2021","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.idc.2025.11.010_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jacamr\/dlac086","article-title":"Clinical and microbiological evaluation of temocillin for bloodstream infections with Enterobacterales: a Belgian single-centre retrospective study","volume":"4","author":"Oosterbos","year":"2022","journal-title":"JAC Antimicrobial Resist"},{"key":"10.1016\/j.idc.2025.11.010_bib20","unstructured":"Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections (TEMO-CARB). ClinicalTrials.gov ID: NCT03543436."},{"issue":"4","key":"10.1016\/j.idc.2025.11.010_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antibiotics11040493","article-title":"Temocillin: applications in antimicrobial stewardship as a potential Carbapenem-sparing antibiotic","volume":"11","author":"Lupia","year":"2022","journal-title":"Antibiotics"},{"issue":"5","key":"10.1016\/j.idc.2025.11.010_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antibiotics14050528","article-title":"Breaking through resistance: a comparative review of new \u03b2-lactamase inhibitors (Avibactam, Vaborbactam, Relebactam) against multidrug-resistant superbugs","volume":"14","author":"Karaiskos","year":"2025","journal-title":"Antibiotics"},{"issue":"5","key":"10.1016\/j.idc.2025.11.010_bib23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2025.11.010_bib24","first-page":"1","article-title":"Pivmecillinam for treatment of uncomplicated urinary tract infection : new efficacy analysis","volume":"26","author":"Lodise","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2025.11.010_bib25","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1093\/jac\/dky230","article-title":"Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: a prospective, multicentre, observational cohort study","volume":"73","author":"Bollestad","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.idc.2025.11.010_bib26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1155\/1993\/875916","article-title":"Containing Cefoxitin costs through a program to curtail use in surgical prophylaxis","volume":"4","author":"Taylor","year":"1993","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"1","key":"10.1016\/j.idc.2025.11.010_bib27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12879-016-1770-1","article-title":"Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems","volume":"16","author":"Fukuchi","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"10","key":"10.1016\/j.idc.2025.11.010_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofad502","article-title":"Efficacy and safety of Cefmetazole for bacteremia caused by extended-spectrum \u03b2-lactamase-producing Enterobacterales vs Carbapenems: a retrospective study","volume":"10","author":"Kashihara","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2025.11.010_bib29","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1128\/AAC.00701-15","article-title":"Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-\u03b2-lactamase-producing Escherichia coli bacteremia","volume":"59","author":"Matsumura","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.idc.2025.11.010_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/aac.00510-23","article-title":"Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli","volume":"67","author":"Hayakawa","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2025.11.010_bib31","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.diagmicrobio.2015.12.001","article-title":"In vitro activities and detection performances of cefmetazole and flomoxef for extended-spectrum \u03b2-lactamase and plasmid-mediated AmpC \u03b2-lactamase-producing Enterobacteriaceae","volume":"84","author":"Matsumura","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.idc.2025.11.010_bib32","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/IDR.S146923","article-title":"Clinical benefit of ertapenem compared to flomoxef for the treatment of cefotaximeresistant enterobacteriaceae bacteremia","volume":"11","author":"Lee","year":"2018","journal-title":"Infect Drug Resist"},{"issue":"1","key":"10.1016\/j.idc.2025.11.010_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-12-206","article-title":"Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum \u03b2-lactamase producing klebsiella pneumoniae in patients on maintenance hemodialysis","volume":"12","author":"Yang","year":"2012","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2025.11.010_bib34","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ijantimicag.2015.07.020","volume":"46","author":"Lee","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idc.2025.11.010_bib35","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/jac\/dkab468","article-title":"Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales","volume":"77","author":"Darlow","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.idc.2025.11.010_bib36","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/jac\/dkac038","article-title":"Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance","volume":"77","author":"Darlow","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.idc.2025.11.010_bib37","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1093\/jac\/dkz149","article-title":"ESBLs and resistance to ceftazidime\/avibactam and ceftolozane\/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa","volume":"74","author":"Ortiz De La Rosa","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2025.11.010_bib38","first-page":"1","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","volume":"7","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2025.11.010_bib39","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/cid\/ciae332","article-title":"Rates of resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam among patients treated for multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia","volume":"80","author":"Shah","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2025.11.010_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2019.114925","article-title":"In vitro activity of ceftolozane\/tazobactam against phenotypically defined extended-spectrum \u03b2-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016)","volume":"96","author":"Karlowsky","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2025.11.010_bib41","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/jac\/dkw374","article-title":"Efficacy of ceftolozane\/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of phase 3 clinical trials","volume":"72","author":"Popejoy","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2025.11.010_bib42","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.3390\/antibiotics12111591","article-title":"Antimicrobial activities of Aztreonam-Avibactam and comparator agents against Enterobacterales analyzed by ICU and non-ICU wards, infection sources, and geographic regions: ATLAS program 2016\u20132020","volume":"12","author":"Pi\u00e9rard","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.idc.2025.11.010_bib43","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jgar.2020.04.023","article-title":"Genetic diversity and in vitro activity of ceftazidime\/avibactam and aztreonam\/avibactam against imipenem-resistant Enterobacteriaceae isolates in Southwest China: a single-centre study","volume":"22","author":"Wei","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.idc.2025.11.010_bib44","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jgar.2022.06.018","article-title":"In vitro activity of aztreonam\/avibactam against isolates of Enterobacterales collected globally from ATLAS in 2019","volume":"30","author":"Rossolini","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.idc.2025.11.010_bib45","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jgar.2025.06.002","article-title":"Activity of aztreonam-avibactam and ceftazidime-avibactam against \u03b2-lactamase-producing Enterobacterales isolates from United States hospitals","volume":"44","author":"Deshpande","year":"2025","journal-title":"J Glob Antimicrob Resist"},{"issue":"9","key":"10.1016\/j.idc.2025.11.010_bib46","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s10096-023-04645-2","article-title":"In vitro activity of aztreonam\u2013avibactam against Enterobacterales isolates collected in Latin America, Africa\/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019\u20132021","volume":"42","author":"Wise","year":"2023","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2025.11.010_bib47","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2025.11.010_bib48","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1128\/AAC.01695-15","article-title":"In vitro antimicrobial activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including Carbapenem-resistant strains","volume":"60","author":"Kohira","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2025.11.010_bib49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.diagmicrobio.2025.116993","article-title":"In-vitro activity of cefepime\/enmetazobactam against extended spectrum \u03b2-lactamases and\/or ampC producing Enterobacterales and Pseudomonas aeruginosa collected across India","volume":"113","author":"Bakthavatchalam","year":"2025","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.idc.2025.11.010_bib50","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jgar.2021.02.031","article-title":"Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016\u20132018 from USA and Europe: genotypic analysis of \u03b2-lactamases and comparative in vitro activity of cefepime\/enmetazobactam","volume":"25","author":"Belley","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"issue":"13","key":"10.1016\/j.idc.2025.11.010_bib51","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jama.2022.17034","article-title":"Effect of Cefepime\/Enmetazobactam vs Piperacillin\/Tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis: a randomized clinical trial","volume":"328","author":"Kaye","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.idc.2025.11.010_bib52","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jgar.2025.06.013","article-title":"In vitro activity of sulopenem and comparator agents against U.S. Enterobacterales clinical isolates collected during the SENTRY antimicrobial surveillance program in 2023","volume":"44","author":"Aronin","year":"2025","journal-title":"J Glob Antimicrob Resist"},{"issue":"12","key":"10.1016\/j.idc.2025.11.010_bib53","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1093\/jac\/dkac333","article-title":"In vitro activity of sulopenem against 1880 bacterial pathogens isolated from Canadian patients with urinary tract infections (CANWARD, 2014-21)","volume":"77","author":"Walkty","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.idc.2025.11.010_bib54","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1093\/jac\/dkad099","article-title":"In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program","volume":"78","author":"Maher","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2025.11.010_bib55","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/cid\/ciac738","article-title":"Sulopenem or Ciprofloxacin for the treatment of uncomplicated urinary tract infections in women: a phase 3, randomized trial","volume":"76","author":"Dunne","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2025.11.010_bib56","first-page":"2025","article-title":"P-1107. Oral Sulopenem\/probenecid for Uncomplicated Urinary Tract Infections (uUTI): results from the REASSURE trial","volume":"12","author":"Puttagunta","year":"2025","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2025.11.010_bib57","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/cid\/ciac704","article-title":"Sulopenem for the treatment of complicated urinary tract infections including pyelonephritis: a phase 3, randomized trial","volume":"76","author":"Dunne","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2025.11.010_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.02385-20","article-title":"In vitro and in vivo characterization of tebipenem, an orally active carbapenem, against biothreat pathogens","volume":"65","author":"Clayton","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.idc.2025.11.010_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/aac.01214-22","article-title":"In vitro activity of Tebipenem against various resistant subsets of Escherichia coli causing urinary tract infections in the United States (2018 to 2020)","volume":"66","author":"Mendes","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.idc.2025.11.010_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00603-19","article-title":"Pharmacodynamics of tebipenem: new options for oral treatment of multidrug-resistant gram-negative infections","volume":"63","author":"McEntee","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2025.11.010_bib61","doi-asserted-by":"crossref","first-page":"106733","DOI":"10.1016\/j.ijantimicag.2023.106733","article-title":"Antimicrobial activity of Tebipenem and comparators against Enterobacterales from diverse outpatient centers and nursing homes in the United States","volume":"61","author":"Asempa","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.idc.2025.11.010_bib62","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02057-22","article-title":"Contemporary evaluation of Tebipenem in vitro activity against Enterobacterales clinical isolates causing urinary tract infections in US Medical Centers (2019\u20132020)","volume":"11","author":"Mendes","year":"2023","journal-title":"Microbiol Spectr"},{"issue":"5","key":"10.1016\/j.idc.2025.11.010_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jacamr\/dlac105","article-title":"Determining the in vitro susceptibility of tebipenem, an oral carbapenem, against third-generation cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae isolated from bloodstream infections","volume":"4","author":"Ranasinghe","year":"2022","journal-title":"JAC Antimicrobial Resist"},{"issue":"14","key":"10.1016\/j.idc.2025.11.010_bib64","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa2105462","article-title":"Oral tebipenem pivoxil hydrobromide in complicated urinary tract infection","volume":"386","author":"Eckburg","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.idc.2025.11.010_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105902","article-title":"Faropenem resistance causes in vitro cross-resistance to carbapenems in ESBL-producing Escherichia coli","volume":"55","author":"Gandra","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.idc.2025.11.010_bib66","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/jac\/dkm063","article-title":"Activity of faropenem against cephalosporin-resistant Enterobacteriaceae","volume":"59","author":"Mushtaq","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2025.11.010_bib67","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jiac.2016.01.010","article-title":"Fosfomycin: resurgence of an old companion","volume":"5","author":"Sastry","year":"2016","journal-title":"J Infect Chemother"},{"issue":"4","key":"10.1016\/j.idc.2025.11.010_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/mBio.00749-17","article-title":"Widespread Fosfomycin resistance in gram-negative bacteria attributable to the chromosomal fosA gene","volume":"8","author":"Ito","year":"2017","journal-title":"mBio"},{"issue":"12","key":"10.1016\/j.idc.2025.11.010_bib69","doi-asserted-by":"crossref","first-page":"7355","DOI":"10.1128\/AAC.01071-15","article-title":"Clinical appraisal of Fosfomycin in the era of antimicrobial resistance","volume":"59","author":"Sastry","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2025.11.010_bib70","doi-asserted-by":"crossref","first-page":"e2137277","DOI":"10.1001\/jamanetworkopen.2021.37277","article-title":"Effectiveness of Fosfomycin for the treatment of multidrug-resistant Escherichia coli bacteremic urinary tract infections: a randomized clinical trial","volume":"5","author":"Sojo-Dorado","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.idc.2025.11.010_bib71","doi-asserted-by":"crossref","first-page":"a027029","DOI":"10.1101\/cshperspect.a027029","article-title":"Aminoglycosides: an overview","volume":"6","author":"Krause","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"10.1016\/j.idc.2025.11.010_bib72","first-page":"458","article-title":"Aminoglycoside versus carbapenem or piperacillin\/tazobactam treatment for bloodstream infections of urinary source caused by gram-negative ESBL-producing Enterobacteriaceae","volume":"75","author":"Zohar","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2025.11.010_bib73","first-page":"1","article-title":"Bacterial diversity and antibiotic resistance patterns of community-acquired urinary tract infections in mega size clinical samples of egyptian patients: a cross-sectional study","volume":"16","author":"Tarek","year":"2024","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.idc.2025.11.010_bib74","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0732-8893(02)00470-4","article-title":"Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000)","volume":"44","author":"Gales","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2025.11.010_bib75","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1177\/10600280251315950","article-title":"Nitrofurantoin versus comparators in the treatment of cystitis due to extended-spectrum \u03b2-lactamase\u2013producing enterobacterales: a multicenter cohort study","volume":"59","author":"Thabit","year":"2025","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.idc.2025.11.010_bib76","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/jgid.jgid_72_17","article-title":"Nitrofurantoin and Fosfomycin for extended spectrum \u03b2-lactamases producing Escherichia coli and Klebsiella pneumoniae","volume":"10","author":"Tulara","year":"2018","journal-title":"J Glob Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2025.11.010_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00284-025-04271-5","article-title":"Molecular characterization of Escherichia coli causing community-acquired urinary tract infections in a suburban area in West Bengal, India: dispersal of multidrug-resistant epidemic ST131 clone carrying CTX-M-1","volume":"82","author":"Biswas","year":"2025","journal-title":"Curr Microbiol"},{"key":"10.1016\/j.idc.2025.11.010_bib78","article-title":"Regional variations in antimicrobial susceptibility of community-acquired uropathogenic Escherichia coli in India: findings of a multicentric study highlighting the importance of local antibiograms","volume":"11","author":"Rizvi","year":"2024","journal-title":"IJID Reg"},{"issue":"3","key":"10.1016\/j.idc.2025.11.010_bib79","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4103\/2279-042X.162363","article-title":"Antimicrobial susceptibility pattern of extended-spectrum \u03b2-lactamase producing Klebsiella pneumoniae clinical isolates in an Indian tertiary hospital","volume":"4","author":"Singh","year":"2015","journal-title":"J Res Pharm Pract"},{"issue":"2","key":"10.1016\/j.idc.2025.11.010_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/acmi.0.000321","article-title":"Prevalence and resistance pattern of uropathogens from community settings of different regions: an experience from India","volume":"4","author":"Mohapatra","year":"2022","journal-title":"Access Microbiol"},{"issue":"1","key":"10.1016\/j.idc.2025.11.010_bib81","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/mdr.2021.0010","article-title":"Antimicrobial resistance trends of Escherichia coli isolates from outpatient and inpatient urinary infections over a 20-year period","volume":"28","author":"Milano","year":"2022","journal-title":"Microb Drug Resist"},{"issue":"7","key":"10.1016\/j.idc.2025.11.010_bib82","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00345-015-1718-x","article-title":"Extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years","volume":"34","author":"Toner","year":"2016","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.idc.2025.11.010_bib83","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/8755122515599407","article-title":"Are fluoroquinolones appropriate for the treatment of extended-spectrum \u03b2-lactamase-producing gram-negative bacilli?","volume":"32","author":"Wiener","year":"2016","journal-title":"J Pharm Technol"},{"issue":"2","key":"10.1016\/j.idc.2025.11.010_bib84","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1086\/380645","article-title":"Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum \u03b2-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin","volume":"38","author":"Endimiani","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2025.11.010_bib85","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jmii.2015.08.012","article-title":"Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae","volume":"50","author":"Lo","year":"2017","journal-title":"J Microbiol Immunol Infect"},{"issue":"8","key":"10.1016\/j.idc.2025.11.010_bib86","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jiac.2017.05.005","article-title":"A randomized controlled trial of sitafloxacin vs. ertapenem as a switch therapy after treatment for acute pyelonephritis caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli: a pilot study","volume":"23","author":"Malaisri","year":"2017","journal-title":"J Infect Chemother"},{"issue":"2","key":"10.1016\/j.idc.2025.11.010_bib87","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijantimicag.2019.05.004","article-title":"Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum \u03b2-lactamase (ESBL) or AmpC \u03b2-lactamase: a propensity score study","volume":"54","author":"Meije","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.idc.2025.11.010_bib88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/aac.01525-22","article-title":"Antimicrobial activity of gepotidacin tested against Escherichia coli and Staphylococcus saprophyticus isolates causing urinary tract infections in Medical Centers Worldwide (2019 to 2020)","volume":"67","author":"Arends","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2025.11.010_bib89","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5582\/ddt.2025.01028","article-title":"Gepotidacin: the first-in-class triazaacenaphthylene antibiotic approved for the treatment of uncomplicated urinary tract infections","volume":"19","author":"Hu","year":"2025","journal-title":"Drug Discov Ther"},{"key":"10.1016\/j.idc.2025.11.010_bib90","first-page":"2023","article-title":"Efficacy and safety of oral gepotidacin in the treatment of uncomplicated urinary tract infection: results of two randomized, multicentre phase 3 trials (EAGLE-2 and EAGLE-3)","author":"Wagenlehner","year":"2023","journal-title":"BSAC UTI Conference"},{"issue":"11","key":"10.1016\/j.idc.2025.11.010_bib91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/spectrum.01144-24","article-title":"Cefepime-taniborbactam demonstrates potent in vitro activity vs Enterobacterales with blaOXA-48","volume":"12","author":"Mojica","year":"2024","journal-title":"Microbiol Spectr"},{"issue":"1","key":"10.1016\/j.idc.2025.11.010_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/aac.01281-22","article-title":"In vitro activity of Cefepime-Taniborbactam and comparators against clinical isolates of Gram-Negative Bacilli from 2018 to 2020: results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program","volume":"67","author":"Karlowsky","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.idc.2025.11.010_bib93","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/jac\/dkae329","article-title":"Cefepime-taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018-22","volume":"79","author":"Karlowsky","year":"2024","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.idc.2025.11.010_bib94","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1093\/jac\/dkaa053","article-title":"In vitro activity of the novel \u03b2-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China","volume":"75","author":"Wang","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.idc.2025.11.010_bib95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/aac.00236-24","article-title":"Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection","volume":"68","author":"Moeck","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2025.11.010_bib96","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/jac\/dkw593","article-title":"In vitro activity of cefepime\/zidebactam (WCK 5222) against Gram-negative bacteria","volume":"72","author":"Livermore","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.idc.2025.11.010_bib97","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1093\/jac\/dkz294","article-title":"Activity of cefepime\/zidebactam (WCK 5222) against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York City medical centres","volume":"74","author":"Khan","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.idc.2025.11.010_bib98","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1093\/jac\/dkab141","article-title":"In vitro activity of imipenem\/relebactam, meropenem\/vaborbactam, ceftazidime\/avibactam, cefepime\/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan","volume":"76","author":"Kuo","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.idc.2025.11.010_bib99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/jcm.01657-22","article-title":"Determination of MIC quality control ranges for ceftibuten-inhibitor combination","volume":"61","author":"Huband","year":"2023","journal-title":"J Clin Microbiol"},{"issue":"5","key":"10.1016\/j.idc.2025.11.010_bib100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/aac.01867-24","article-title":"Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of Enterobacterales from outpatient centers and nursing homes across the United States (2022\u20132024)","volume":"69","author":"Fouad","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2025.11.010_bib101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/aac.01346-22","article-title":"In vitro activity of Ceftibuten-Avibactam against \u03b2-Lactamase positive Enterobacterales from the ATLAS Global Surveillance Program","volume":"67","author":"Karlowsky","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2025.11.010_bib102","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10096-023-04562-4","article-title":"Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with urinary tract infections (2021)","volume":"42","author":"Sader","year":"2023","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2025.11.010_bib103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/aac.02168-21","article-title":"The ultrabroad-spectrum \u03b2-lactamase inhibitor QPX7728 restores the potency of multiple oral \u03b2-lactam antibiotics against \u03b2-lactamase-producing strains of resistant Enterobacterales","volume":"66","author":"Lomovskaya","year":"2022","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552025001047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552025001047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:34:04Z","timestamp":1773952444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552025001047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":103,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0891552025001047"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2025.11.010","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Strategies for Extended-Spectrum \u03b2-Lactamase-Producing Organisms","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2025.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}